Medicine
Sinuva 1350 mcg implant
Sinuva 1350 mcg implant is a prescription medicine containing Mometasone furoate for intrasinal use, marketed by Intersect ENT, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store the SINUVA Sinus Implant at 20° C– 25°C (68°F–77°F), excursions…
Key facts
- Active ingredient (INN)
- Mometasone furoate
- Brand
- Sinuva
- Strength
- 1350 mcg
- Dosage form
- Implant
- Route
- Intrasinal
- Packs
- 1 pouch
- Marketing authorisation holder
- Intersect ENT
- Manufacturer
- Intersect ENT
- Origin register
- US FDA, United States
- Storage
- Store the SINUVA Sinus Implant at 20° C– 25°C (68°F–77°F), excursions permitted at 15°C –30°C (59°F– 86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- R01AD09 Mometasone furoate
- HS code (indicative)
- 3004.32Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 1 February 2018
- Identifiers
- RxCUI 1995983, 1995988DailyMed set ID e33c1b23-cdc6-4f64-94ba-24b0b42c09bfNDC 10599-003Application NDA209310
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 pouch in 1 carton / 1 implant in 1 pouch | 10599-003-01 | Intersect ENT | 1 February 2018 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 30 April 1987 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Mometasone furoate
Clinical summary
Mometasone furoate is a corticosteroid indicated for the maintenance treatment of asthma as prophylactic therapy in adult and pediatric patients 4 years of age and older, among other approved uses. MedsAcross supplies Mometasone furoate for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Mometasone furoateFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- ASMANEX prescribing information (Organon) · U.S. National Library of Medicine, DailyMed
Need Sinuva 1350 mcg implant for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.